ICG132 / iCell Gene Therap, Guiqidan Biomedicine 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ICG132 / iCell Gene Therap, Guiqidan Biomedicine
SuperCARTRRB1.0, ChiCTR1900026083: CD19/CD20/CARVAC-targeted Chimeric antigen receptor gene-modified T cells therapy in Patients with relapsed/refractory B cell malignancies

Recruiting
N/A
24
 
infusion of 1×10*6 ICG132 ;infusion of 2×10*6 ICG132 ;infusion of 4×10*6 ICG132 ;infusion of 8×10*6 ICG132 ;infusion of 1×10*6 ICG134 ;infusion of 2×10*6 ICG134 ;infusion of 4×10*6 ICG134 ;infusion of 8×10*6 ICG134
The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University, Guiguidan Biomedicine(Zhongshan) Co. Ltd.
relapsed/refractory B cell malignancies
 
 

Download Options